Stabilized Nucleic Acids Encoding Messenger Ribonucleic Acid (mRNA)
AssigneeIntellia Therapeutics, Inc.
InventorChristian Dombrowski
Life of this patent
Estimating the term…
Abstract
This disclosure relates to the field of poly-adenylated (poly-A) tails. In some embodiments, a DNA encodes a poly-A tail located 3′ to nucleotides encoding a protein of interest, wherein the poly-A tail comprises one or more non-adenine nucleotide.
Claims46
A DNA comprising nucleotides encoding a poly-adenylated (poly-A) tail located 3′ to nucleotides encoding a protein of interest, wherein the poly-A tail comprises a first homopolymer sequence of at least 8 consecutive adenine (A) nucleotides and an interrupting sequence comprising one or more non-adenine (A) nucleotides.
The DNA of any preceding claim, wherein the poly-A tail comprises or contains 1, 2, 3, 4, or 5 consecutive non-adenine nucleotides every 8-50 consecutive adenine nucleotides.
The DNA of any preceding claim, wherein the more than one non-adenine nucleotide or more than one consecutive stretch of 2-10 non-adenine nucleotides are irregularly spaced within the poly-A tail.
The DNA of any preceding claim, wherein the poly-A tail comprises or contains one non-adenine nucleotide or 2, 3, 4, or 5 consecutive non-adenine nucleotides every 12 consecutive adenine nucleotides.
The DNA of any preceding claim, wherein the poly-A tail comprises or contains one non-adenine nucleotide or 2, 3, 4, or 5 consecutive non-adenine nucleotides every 16 consecutive adenine nucleotides.
The DNA of any preceding claim, wherein the poly-A tail comprises or contains one non-adenine nucleotide or 2, 3, 4, or 5 consecutive non-adenine nucleotides every 25 consecutive adenine nucleotides.
The DNA of any preceding claim, wherein the poly-A tail comprises or contains one non-adenine nucleotide or 2, 3, 4, or 5 consecutive non-adenine nucleotides every 30 consecutive adenine nucleotides.
The DNA of any preceding claim, wherein the poly-A tail comprises or contains one non-adenine nucleotide or 2, 3, 4, or 5 consecutive non-adenine nucleotides every 39 consecutive adenine nucleotides.
The DNA of any preceding claim, wherein the non-adenine nucleotide is guanine, cytosine, or thymine.
The DNA of any preceding claim, wherein the non-adenine nucleotide consists of one non-adenine nucleotide selected from guanine, cytosine, and thymine.
The DNA of any preceding claim, wherein the non-adenine nucleotides comprise two non-adenine nucleotides selected from one or more of guanine, cytosine, and thymine.
The DNA of any preceding claim, wherein the non-adenine nucleotides comprise three non-adenine nucleotides selected from one or more of guanine, cytosine, and thymine.
The DNA of any preceding claim, wherein the adenine nucleotides are adenosine monophosphate.
The DNA of any preceding claim, wherein the protein is a therapeutic protein.
A mRNA encoded by the DNA of any one of the preceding claims.
The DNA of any preceding claim, wherein the DNA is within a vector.
Dependencies are inferred from the claim text.